Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy

References

• Kwak L W, Halpern J, Olshen R A, Horning S J. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963–977
   PubMed Web of Science ®Google Scholar
• Landgren O, Algernon C, Axdorph U, Nilsson B, Wedelin C, Porwit-MacDonald A, et al. Hodgkin's lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 2003; 88: 438–444
   PubMed Web of Science ®Google Scholar
• Carde P, MacKintosh F R, Rosenberg S A. A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983; 1: 146–153
   PubMed Web of Science ®Google Scholar
• van Rijswijk R E, Haanen C, Dekker A W, de Meijer A J, Verbeek J. Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease. J Clin Oncol 1989; 7: 1776–1782
   PubMed Web of Science ®Google Scholar
• Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci 1988; 24: 533–538
   PubMedGoogle Scholar
• Canellos G P, Anderson J R, Propert K J, Nissen N, Cooper M R, Henderson E S, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478–1484
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252–259
   PubMed Web of Science ®Google Scholar
• Duggan D B, Petroni G R, Johnson J L, Glick J H, Fisher R I, Connors J M, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003; 21: 607–614
   PubMed Web of Science ®Google Scholar
• Clarke K, Grigg A. Intermittent G-CSF to maintain dose intensity of chemotherapy for Hodgkin's disease. Leuk Lymphoma 1995; 19: 521–522
   PubMed Web of Science ®Google Scholar
• Rueda A, Sevilla I, Guma J, Ribelles N, Miramon J, De Las Nieves M A, et al. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD. Leuk Lymphoma 2001; 41: 353–358
   PubMed Web of Science ®Google Scholar
• Straus D J, Portlock C S, Qin J, Myers J, Zelenetz A D, Moskowitz C, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood 2004; 104: 3483–3489
   PubMed Web of Science ®Google Scholar
• Liang K, Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13–22
   Web of Science ®Google Scholar
• Zeger S L, Liang K Y, Albert P S. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44: 1049–1060
   PubMed Web of Science ®Google Scholar
• Zeger S L, Liang K Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121–130
   PubMed Web of Science ®Google Scholar
• Kalbeisch J D, Prentice R L. The Statistical analysis of failure time data. Wiley, New York 1980
   Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506–1514
   PubMed Web of Science ®Google Scholar
• Lyman G H, Delgado D J. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003; 98: 2402–2409
   PubMed Web of Science ®Google Scholar
• Gustavsson A. G-CSF (filgrastim) as an adjunct to MOPP/ABVD therapy in Hodgkin's disease. Acta Oncol 1997; 36: 483–488
   PubMed Web of Science ®Google Scholar
• Picozzi V J, Pohlman B L, Morrison V A, Lawless G D, Lee M W, Kerr R O, et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Huntingt) 2001; 15: 1296–1306
   PubMed Web of Science ®Google Scholar
• Chrischilles E A, Link B K, Scott S D, Delgado D J, Fridman M. Factors associated with early termination of CHOP therapy and the impact on survival among patients with chemosensitive intermediate-grade non-Hodgkin's lymphoma. Cancer Control 2003; 10: 396–403
   PubMedGoogle Scholar
• Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, et al. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998; 16: 3810–3821
   PubMed Web of Science ®Google Scholar
• Bohlius J, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database Syst Rev 2004; CD003189
   Google Scholar
• Bohlius J, Reiser M, Schwarzer G, Engert A. Impact of granulocyte colony-stimulating factor (CSF) and granulocyte-macrophage CSF in patients with malignant lymphoma: a systematic review. Br J Haematol 2003; 122: 413–423
   PubMed Web of Science ®Google Scholar
• Gerhartz H H, Engelhard M, Meusers P, Brittinger G, Wilmanns W, Schlimok G, et al. Randomized, double-blind, placebo-controlled, phase III study of recombinant human granulocyte-macrophage colony-stimulating factor as adjunct to induction treatment of high-grade malignant non- Hodgkin's lymphomas. Blood 1993; 82: 2329–2339
   PubMed Web of Science ®Google Scholar
• Pettengell R, Gurney H, Radford J A, Deakin D P, James R, Wilkinson P M, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–1436
   PubMed Web of Science ®Google Scholar
• Silvestri F, Fanin R, Velisig M, Barillari G, Virgolini L, Zaja F, et al. The role of granulocyte colony-stimulating factor (filgrastim) in maintaining dose intensity during conventional-dose chemotherapy with ABVD in Hodgkin's disease. Tumori 1994; 80: 453–458
   PubMed Web of Science ®Google Scholar
• Martin W, Habermann T, Colgan J, Ristow K, Ansell S. G-CSF administration increases pulmonary toxicity for Hodgkin's disease patients treated with bleomycin-containing chemotherapy. Blood 2004; 104: 371A
   Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER). Program Public-Use Data. 1973 – 1999, Program Web Site, Data Quality. http://www.seer.gov
   Google Scholar